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Preeclampsia, a relatively common pregnancy disorder, is one of the major causes of maternal and fetal morbidity and mortality.
Despite numerous research, the etiology of this syndrome remains not well understood as the pathogenesis of preeclampsia is
complex, involving interaction between genetic, immunologic, and environmental factors. Preeclampsia, originating in placenta
abnormalities, is induced by the circulating factors derived from the abnormal placenta. Recent work has identified various
molecularmechanisms related to placenta development, including renin-angiotensin system, 1, 25-dihydroxyvitaminD, and lipoxin
A4. Interestingly, advances suggest that vacuolar ATPase, a keymolecule in placentation, is closely associated with them.Therefore,
this intriguing molecule may represent an important link between various causes of preeclampsia. Here, we review that vacuolar
ATPase works as a key link between multiple causes of preeclampsia and discuss the potential molecular mechanisms. The novel
findings outlined in this review may provide promising explanations for the causation of preeclampsia and a rationale for future
therapeutic interventions for this condition.
1. Preeclampsia
Preeclampsia, a pregnancy-complicated syndrome, is one of
the leading causes of maternal and fetal morbidity and
mortality [1]. This potentially dangerous condition affects
approximately 2–7% of all pregnancies in the western world,
but the incidence in developing countries can be greater [1, 2].
Preeclampsia is a maternal systemic symptom of late second
or third trimester of pregnancy, characterized by hyperten-
sion, proteinuria, fetal intrauterine growth restriction, and
other maternal abnormity [3]. In the worst cases, it may
threaten the survival of both mother and baby [4]. Now,
except for induced delivery, there is no effective treatment
to cure it. Risk factors involved in preeclampsia have been
increasingly identified (Table 1), and emergence of any risk
factormay cause a woman to develop preeclampsia. However,
exact pathogenesis of this disorder remains uncertain since
numerous research into the etiology of preeclampsia did
not progress significantly. Understanding the detailed mech-
anism underlying preeclampsia will help to develop novel
prophylactic and therapeutic interventions for this condition.
The current understanding about preeclampsia is that it
appears to develop in a two-stage progress, with a preclinical
initial stage which has an abnormal placenta, followed by a
second stage during which release of soluble factors from
hypoxic placenta leads to various observed maternal condi-
tions, including hypertension, proteinuria, and generalized
damage to the maternal organ. Preeclampsia is commonly
considered to result from the presence of a poor placenta
since the only effective cure of the clinical syndrome is
delivery of the placenta. Placentation occurs from weeks 6
to 18 of gestation, during which extravillous cytotrophoblast
invasion is required for extensive remodeling of maternal
spiral arteries [4]. In preeclampsia, placenta is extremely
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Table 1: Risk factors that may induce development of preeclampsia.
Related category Risk factors
Genetic factors
Individual genetic susceptibility [1]
Polymorphisms of specific genes [1]
Preeclampsia history [12]
Family history [12]
Immunologic factors Paternal alloantigens [4]
Maternal pre-existing factors
Autoimmune conditions [12]
Hypertension [12]
Diabetes [12]
Renal disease [12]
Obesity [12]
Other factors
Malnutrition [13]
Primiparity [12]
Multiple pregnancies [12]
Maternal age [12]
shallow because of inadequate trophoblast invasion and
deficient remodeling of spiral arteries [5, 6]. Implantation
failure of placenta predisposes it to hypoxia and oxidative
stress [7], thus resulting in a maternal systemic inflammatory
response characterized by enhanced expression of inflamma-
tory mediators [5]. It was found that dysfunctional placenta
can release adverse factors into the maternal circulation,
causing the clinical features of this condition. These fac-
tors include some hormones or chemical substances, such
as sFlt1 (soluble fms-like tyrosine kinase 1) [4], AT1-AA
(angiotensin II AT1 receptor auto-antibody) [6], and cardiac
glycosides (marinobufagenin, MBG) [8]. Among these, sFlt1
can cause endothelial dysfunction in the maternal blood
vessels by binding vascular endothelial growth factors and
placental growth factor [4]; AT1-AA can react with the AT1
receptor in a stimulatory fashion similar to angiotensin II
signalling, which could contribute to maternal hypertension
[6]; MBG, involved in the pathogenesis of preeclampsia, has
been demonstrated to cause hypertension, proteinuria, and
intrauterine growth restriction in the ratmodel of preeclamp-
sia [8]. Augmented release of these factors secondary to the
original poor placenta will eventually lead to damage of the
endothelium, metabolism dysfunction, and inflammation as
well as other typical symptoms.
Then, what is the exact mechanism leading to deficient
trophoblast invasion and further poor placenta? Immune
responses and maternal endocrine system can be considered
to be two main elements involved in the development of
placenta. There is evidence suggesting that shallow placenta
is thought to stem from the lack of immune tolerance to
pater-derived fetal antigens [9]. Initial maternal rejection
to the fetoplacenta may be the main reason for inade-
quate spiral arteries remodeling in preeclampsia. During
the normal pregnancy, maternal innate immune response
is physiologically regulated to prevent the rejection to the
fetal allograft.Meanwhile,Th1/Th2activity balance is strongly
shifted toward Th2 activity to maintain the normal fetoma-
ternal interaction [10]. Many have found that maternal T cell
cannot recognize fetal human lymphocyte antigens (HLAs)
rightly and decidua NK cell has an unusual phenotype
in preeclampsia [4]. Moreover, another important differ-
ence found between normal pregnancy and preeclampsia
is the shift of Th1/Th2 balance toward Th1 responses. In
addition to immune maladaptation, it is also found that
maternal endocrine system is perturbed in preeclampsia.
In normal pregnancy, components of renin-angiotensin-
aldosterone system, including renin, angiotensin, and aldos-
terone, are increased, while these hormones are suppressed
in preeclampsia [9]. A recent report found that activation
of mineralocorticoid receptor in trophoblast by maternal
aldosterone appears to be required for trophoblast prolif-
eration and placenta development [11]. Additionally, other
pregnancy-related hormones also make great contribution to
favourable pregnancy outcome. For example, progesterone
plays a dominant role in maintaining uterine quiescence
andmodulating fetomaternal immune response locally, while
estrogen appears also to be a potent immunomodulator in
pregnancy-associated immune function [10]. Aberration in
these hormones level may disrupt homoeostasis of placenta
development, thus causing the onset of preeclampsia even-
tually. Overall, abnormal change in immune responses and
maternal endocrine system throughout pregnancy may be
one explanation for preeclampsia (Figure 1).
Following extensive research into placentation, recent
advances have identified emerging key players relevant to
placenta establishment, including renin-angiotensin system
(RAS), 1, 25-dihydroxyvitaminD (1,25(OH)2D3), and lipoxin
A4. Evidence indicates that aberration in them may disrupt
placenta development, contributing to adverse pregnancy
outcome, such as preeclampsia (described subsequently). V-
ATPase, another key molecule in placentation, is closely
associated with all of them. During normal pregnancy, RAS,
1,25(OH)2D3, and lipoxin A4 may work independently, in
parallel or jointly on the central molecule, V-ATPase, while
V-ATPase also affects them at the same time. Therefore,
the intriguing molecule V-ATPase may represent a key link
between various causes of preeclampsia. In the following
the present review will focus on some new findings about
interaction between V-ATPase and RAS, 1,25(OH)2D3 and
lipoxin A4 in pregnancy, which will provide new insights into
the molecular mechanisms underlying preeclampsia.
2. Vacuolar ATPase
The acidity regulation of intracellular and extracellular envi-
ronment is crucial for a variety of biological processes,
including acidity homeostasis, membrane trafficking, protein
degradation, and sperm maturation [14]. Central to this
regulation is the Vacuolar ATPase (V-ATPase), which is a
large multisubunit complex functioning as an ATP-driven
proton pump. V-ATPase is of significant importance in basic
physiological processes, and it has been implicated in a
number of human diseases, such as renal disease, tumour
metastasis, and bone disease [14]. V-ATPase is composed
of two large domains, V0 and V1. The V0 domain is a
260 kDa membrane-embedded complex that contains six
different subunits (a, d, e, c, c󸀠, and c󸀠󸀠) and functions as
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Stage 1
(preclinical stage)
Abnormal immune responses
(ie. maternal immune
rejection, Thl/Th2 imbalance,
incorrect T cell recognition,
unusual NK cell phenotype)
Disturbed endocrine system
(ie. reduced level of RAS,
progesterone and estrogen)
Defective placenta
(ischemia, hypoxia, oxidative stress)
Stage 2
(clinical stage)
Fetal effects
(ie. IUGR)
Maternal systemic
inﬂammatory response Endothelial dysfunction
Clinical manifestation of preeclampsia
Reduced blood supply Release of placental factors (ie. sFlt-1)
Figure 1: Abnormal immune responses and endocrine system in the development of preeclampsia. Preclinical stage 1 occurs in early
pregnancy when abnormal immune responses and disturbed endocrine system lead to poor placentation resulting in placental hypoxia,
ischemia and oxidative stress. Clinical stage 2 occurs systemically when a defective placenta releases factors into the maternal circulation,
which cause the maternal systemic inflammatory response and endothelial dysfunction that lead to the clinical signs of preeclampsia.
a proton-translocation domain, whereas the V1 domain is a
650 kDa cytoplasmic complex that contains eight different
subunits (A, B, C, D, E, F, G, and H) and functions as
an ATP-hydrolytic domain. It is the structural complexity
of V-ATPase that makes it an important player in various
physiological functions. Many of V-ATPase subunits have
multiple isoforms, and so specificV-ATPase can be composed
of different combinations of these subunit isoforms.
V-ATPase, mediating various physiological processes and
cellular homeostasis, may be closely involved in different
stages of reproduction. In fact, there are many reports
demonstrating that V-ATPase has an important role in all
aspects of mammalian reproduction, such as spermatogene-
sis, fertilization, embryonic implantation, and embryo devel-
opment [15]. On one hand, the acidic microenvironment
regulated by V-ATPase is essential for embryonic devel-
opment following embryonic implantation. On the other
hand, different V-ATPase has specific tissue distribution in
reproduction system and exerts differential crucial function.
Among all of the V-ATPase subunits, subunit “a” is involved
in acrosomal reaction of sperm and embryonic implanta-
tion, both of which provide vital foundation for successful
pregnancy [15]. Subunit “a” is a large membrane-spanning
protein with a hydrophilic cytoplasmic N-terminal domain
and a nine-transmembrane C-terminal domain [14], and it
contains the information necessary to target the V-ATPase to
different cellular destinations and is responsible for proton
transport into the lumen of intracellular vesicles or across
membranes [16]. There are four isoforms of subunit “a” (a1,
a2, a3, and a4), which exhibit diverse tissue distribution
and subcellular location [16]. Isoform 2 of subunit “a”
(ATP6V0A2, referred to as a2V-ATPase) can be detected in
the epididymis, kidney, lung, thymus, spleen, and placenta
[17]. Recently, increasing evidence indicates the crucial role
of a2V-ATPase in placental immune modulation associated
with pregnancy [15]. In early pregnancy, many important
cytokines secreted by placenta trophoblast cells and immune
cells in decidua play a key role in embryonic implantation
and fetomaternal immune tolerance [18]. Interestingly, it is
reported that a2V-ATPase is important in controlling the
expression of these essential cytokines [18]. Thus, the normal
expression and localization of a2V-ATPase in fetoplacental
unit is essential for pregnancy. Jaiswal et al. have reported that
placental a2V-ATPase expression is a link between multiple
causes of spontaneous abortion in mice, and dysfunction of
a2V-ATPase in early pregnancy has been associated not only
with spontaneous abortion but also with preeclampsia and
fetal growth restriction [19]. Another interesting study found
that NOX2/NADPH oxidase regulates antigen crosspresen-
tation in adaptive immunity through changing phagosome
lumen PH, whereas the effect of NOX2/NADPH oxidase
on phagosomal pH is antagonized by V-ATPase, which may
represent a novelmechanism responsible for themaintenance
of immune tolerance [20]. Taken together, these indicate the
importance of V-ATPase in maintaining reproduction pro-
cess and placentation and modulating fetomaternal immune
tolerance in pregnancy, whereas defective V-ATPase may
increase the risk of causing a poor placenta and inducing
preeclampsia (Figure 2).
3. Renin-Angiotensin System, V-ATPase,
and Preeclampsia
The circulating renin-angiotensin system (RAS) is an endo-
crine hormone system that plays a key role in regulating
blood pressure and systemic electrolyte balance. Apart from
systemic circulating RAS, local RAS is present in many
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Dysfunction of V-ATPase
Deficient embryonic implantation Abnormal placental development Fetomaternal immune intolerance
Poor placenta
IUGR Preeclampsia
Figure 2: Abnormal V-ATPase function in the development of preeclampsia. Preclinical stage of preeclampsia occurs in early pregnancy
when dysfunctional V-ATPase activity leads to deficient embryonic implantation, abnormal placental development and fetomaternal immune
intolerance, resulting in poor placenta. Clinical stage of preeclampsia occurs systemically when a defective placenta causes the maternal
systemic inflammatory response and endothelial dysfunction that lead to the clinical signs of preeclampsia.
tissues or organs, such as brain, heart, ovary, and placenta,
and one of the major extrarenal RAS during pregnancy is
the placental RAS [21]. In pregnancy, the circulating RAS
maintains maternal electrolyte balance and blood pressure
homoeostasis, facilitating expanding blood supply for fetus,
while the placental RAS has indispensable role in the utero-
placental unit [21]. Components of placental RAS have been
confirmed to be involved in many molecular events of pla-
cental establishment. A recent review reported that placental
cytotrophoblast is rich in AT1 receptor, and ANG II-AT1
receptor signaling regulates multiple genes associated with
normal trophoblast invasion, such as plasminogen activator
inhibitor-1 (PAI-1), such as soluble fms-like tyrosine receptor-
1 (sFlt-1) and soluble endoglin (s-Eng) [22]. Additionally,
ANG II signaling also activates NF-kappa B and stimulates
the synthesis of reduced nicotinamide-adenine dinucleotide
phosphate (NADPH) oxidase by trophoblast [22]. Moreover,
it has been demonstrated by a recent study that activation
of mineralocorticoid receptor in placental trophoblast by
maternal aldosterone appears to be required for trophoblast
growth and normal fetoplacental function [11]. Therefore, in
response to pregnancy, both systemic RAS and placental RAS
need to be adapted to sustain a healthy pregnancy.
Advances have revealed that maternal RAS is perturbed
in preeclampsia. In an uncomplicated pregnancy, there is
an increase in almost all the components of maternal RAS,
including renin, angiotensin, and aldosterone, but these
hormones are suppressed in preeclampsia [9]. However, the
changes happening in the components of uteroplacental RAS
are different from those observed in circulating RAS. Recent
studies demonstrated that upregulation of the AT1 receptor
expression [23], increase in renin level [24], and enhancement
of ANG II production [25] occur in uteroplacental unit of
preeclamptic women. So, the expression profile of both sys-
temic RAS and placental RAS in preeclampsia differs greatly
from that of healthy uncomplicated pregnancy. Additionally,
there is a growing body of reports indicating the presence
of the angiotensin II type I receptor agonistic autoantibody
(AT1-AA) in preeclamptic women, and this autoantibody
through AT1 receptor signaling can result in dysregulation
of the RAS, then leading to clinical features of preeclampsia
[22]. All abnormalities in both systemic RAS and placental
RAS can cause poor placentation and preeclampsia.
There is accumulating evidence suggesting that compo-
nents of RAS are interrelated to V-ATPase and are essential
for regulating V-ATPase activity. The (pro)renin receptor
((P)RR), encoded in ATP6AP2, plays a key role in activation
of the local RAS, while a truncated form of (P)RR, termed
M8.9, was found to be associatedwith theV-ATPase assembly
and function, implicating a novel role of (P)RR in V-ATPase
activity [26]. Recently, another interesting report indicated
that (P)RR functions as an adaptor between Wnt receptor
andV-ATPase, which is required formediatingWnt signaling
[27]. It was found that angiotensin II has profound effects
on H+ transport and urinary acidification in kidney, mainly
through its regulation on V-ATPase activity, and it has also
been confirmed to stimulate vacuolar H+-ATPase activity
in renal acid-secretory intercalated cells from the outer
medullary collecting duct [28]. Not long before, a report
showed that aldosterone may participate in the regulation of
V-ATPase activity in acid-secretory intercalated cells through
rapid nongenomic stimulatory action and contribute to
urinary acidification [29]. Meanwhile, another study, prior to
this review, described that aldosterone has both genomic and
nongenomic stimulatory effects on V-ATPase in proximal
S3 segments [30]. Considering the content described earlier,
it is reasonable that uteroplacental V-ATPase function is
a key link between RAS and placentation. Therefore, any
aberration in interaction between RAS and V-ATPase may
induce preeclampsia by interfering various processes in
placent development.
4. 1,25-Dihydroxyvitamin D, V-ATPase,
and Preeclampsia
1,25-Dihydroxyvitamin D (1,25(OH)2D3), the active form of
vitamin D, has long been considered to be a leading molecule
in calcium and bone homeostasis. However, in the past years,
it was found that vitaminD receptor (VDR) is present inmost
tissues and many tissues contain the 1,25(OH)2D3 synthase,
25(OH)D3-1𝛼-hydroxylase [31, 32], which makes us begin
to be aware of multiple nonclassic actions of 1,25(OH)2D3.
In fact, advances have shown that 1,25(OH)2D3 deficiency
may increase the risk of developing a wide range of chronic
diseases, including cancer, autoimmune disease, infectious
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disease, and cardiovascular disease [32]. Through binding to
the VDR, 1,25(OH)2D3 can generate a wide array of favorable
nonclassic biological responses that are different from its
classic actions inmaintaining bone and calcium homeostasis,
whereas these nonclassic actions are mainly linked to its reg-
ulation of cell proliferation, cell differentiation, and immune
responses [31]. It is worth emphasizing that some of non-
classic biological effects of 1,25(OH)2D3 have been suggested
to participate in modulation of embryo implantation, feto-
maternal immune tolerance, and placental antimicrobial and
anti-inflammatory responses [33]. Therefore, 1,25(OH)2D3
deficiency in pregnancy may not only impair maternal and
fetal bone health, but also cause various adverse pregnancy
outcomes such as preterm birth, fetal intrauterine growth
restriction, and preeclampsia. Indeed, a clinical study by
Halhali et. al demonstrated that the level of 1,25(OH)2D3 in
both maternal circulation and umbilical cord compartment
is low in preeclampsia [34]. Furthermore, expression and
activity of 25-hydroxyvitamin D-1𝛼-hydroxylase has been
confirmed to be significantly restricted in cultures of pla-
cental syncytiotrophoblast cells frompreeclamptic pregnancy
[35]. So, 1,25(OH)2D3 insufficiency during pregnancy is
potentially associated with increased risk of preeclampsia.
Typical feature of preeclampsia is maternal systemic
inflammatory response, characterized by upregulation of
proinflammatory mediators in both uteroplacental unit and
peripheral circulation. In fact, as described previously, the
systemic inflammatory response in preeclampsia is thought
to stem from initial disorder of fetomaternal immune tol-
erance. Vitamin D, particularly 1,25(OH)2D3, has received
particular attention in recent years as it has been shown to
have important effect on both innate and adaptive immune
systems. Moreover, 1,25(OH)2D3 has been demonstrated to
be essential for modulating tissue-specific immune responses
and preventing chronic inflammation and autoimmunity
[36]. Increasingly, the immunomodulation of 1,25(OH)2D3
has been proposed as a key link between vitamin D and
pregnancy [33]. In addition to be mainly synthesized in
the kidney, 1,25(OH)2D3 can also be locally produced by
immune cells, such as macrophage, dendritic cell, activated
T cell, and probably B cell [36]. In autocrine or paracrine
manner, the local produced 1,25(OH)2D3 can exert a marked
inhibitory effect on adaptive immune responses, promot-
ing humoral Th2 responses whilst suppressing cellular Th1
responses [33, 36]. Also, innate immune cells can be inhib-
ited by 1,25(OH)2D3. For example, 1,25(OH)2D3 is able to
inhibit the differentiation, maturation, and immunostimula-
tory capacity of DCs by decreasing the expression of MHC
class II molecule, CD40, CD80, and CD86 [36]. A recent
report by Saito speculated that imbalance between regulatory
T cell and Th17 cell differentiation may explain pathogenesis
of preeclampsia [37], which provides new light on patho-
physiology of preeclampsia. Interestingly, 1,25(OH)2D3 has
been confirmed to enhance tolerogenic immunity by induc-
ing immunosuppressive Treg [38], while proinflammatory
Th17 cell is suppressed by 1,25(OH)2D3 [39]. In summary,
maternal vitamin D level may influence pregnancy outcome
through a variety of potential mechanisms, and impaired
vitamin D status may lead to preeclampsia.
There is an intimate interaction between vitamin D
and V-ATPase. Indeed, a recent study demonstrated that
in the presence of vitamin D, human osteoclasts express
elevated V-ATPase levels [40]. Meanwhile, this work also
described that 1,25(OH)2D3 can upregulate the activity of
V-ATPase complex [40]. Although the study did not study
the case in pregnancy, it will imply us that 1,25(OH)2D3
may have an important effect on uteroplacental V-ATPase
activity. Moreover, the ability of 1,25(OH)2D3 to regulate
secretion of pregnancy-related hormones may explain its
role in mediating V-ATPase activity. 1,25(OH)2D3 has been
confirmed to be an important player in the upregulation
of estrogen biosynthesis [41], and the previous description
has also revealed that V-ATPase expression is estrogen
dependent [42], which makes it reasonable to speculate that
1,25(OH)2D3 can act on V-ATPase indirectly by influencing
hormones level. Recently, a significative review suggested
that autophagy is a general basis for the multiple health-
promoting effects of vitamin D [43]. Autophagy, depending
on lysosomal self-digestion machinery, is an evolutionarily
conserved self-catabolism process that is essential for cell
growth, development, and homeostasis. To a great extent,
V-ATPase is vital for autophagy since V-ATPase is of great
importance for lysosomal function. Thus, coupled with V-
ATPase, 1,25(OH)2D3 could induce and activate autophagy,
protecting human against many diseases. Autophagy is
induced by several forms of cell stress including hypoxia,
infection, and starvation [43]. If autophagy could not be
initiated properly, disturbance in autophagy will result in a
wide range of disorder. In the case of preeclampsia, abnormal
placentation in early pregnancy predisposes placenta to
ischemia, hypoxia, and oxidative stress, which accumulates
large numbers of apoptotic trophoblast cells at uteroplacental
interface. If not treated through cell autophagy, the apoptotic
trophoblast cells may impair further placenta development
seriously and induce onset of preeclampsia. Thus, maternal
vitamin D deficiency may trigger preeclampsia through
affecting V-ATPase activity, which seems to represent a
general and basic pathogenesis of preeclampsia.
5. Lipoxin A4, V-ATPase, and Preeclampsia
Lipoxin, the “stop signal” for inflammation, is the first medi-
ator recognized to have dual anti-inflammatory and prores-
olution activities [44]. In mammals, lipoxin A4 is the major
lipoxin that has potent actions in vivo. Lipoxin A4, mainly
depending on transcellular biosynthesis in the inflammation
microenvironment, is derived from arachidonic acid by the
sequential action of lipoxygenase (LOX). Leukocyte/platelet
interaction, involving two key enzymes 5-LOX and 12-LOX,
is one of the most important synthesis forms. This pattern
of biosynthesis involves the initiation of arachidonic acid
oxygenation by 5-LOX in leukocytes, and then the inter-
mediate leukotriene A4 is converted into lipoxin A4 by 12-
LOX in platelets. Interestingly, our previous results indicated
that platelet-derived microparticles containing 12-LOX can
be transferred to leukotriene-producing mast cells, which
represents a new pathway for lipoxin A4 biosynthesis in vivo
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[45]. Lipoxin A4 can act on many cell types including blood
cell, neural cell, and stromal cell [44]. Lipoxin A4 displays
selective regulation for leukocyte responses and trafficking
in vivo through activating its specific receptor, ALXR. For
example, in neutrophils, lipoxin A4-ALXR interaction blocks
neutrophil migration and infiltration into sites of inflam-
mation. By contrast, in monocytes, LXA4-ALXR interaction
stimulates monocyte recruitment and the phagocytosis of
apoptotic neutrophils. Recently, we found that lipoxin A4
can suppress hepatocellular carcinoma via remodeling tumor
microenvironment [46].Moreover, we found thatALXR (also
termed FPR2) has an appreciable pleiotropic regulator role in
macrophage polarization, and LXA4-inducedM2a+M2c-like
macrophage phenotype showed antitumorigenesis activities
[47]. Taken together, all previous results show us the key role
of lipoxin A4 as an essential modulator of immune response
and homoeostasis.
Inflammatory processes are central to a series of preg-
nancy events, while inflammation dysregulation is a typical
feature of pregnant complications, such as preeclampsia and
preterm. Normal pregnancy is characterised by a state of
mild maternal systemic inflammation, which develops when
pregnancy is progressing [5]. Although preeclampsia is also
associated with inflammatory response, it is an exaggerated
maternal systemic inflammatory response [6]. In fact, this
disorder is an extreme condition of a range of uncontrolled
inflammatory responses induced by abnormal pregnancy.
LipoxinA4, as an anti-inflammatory and proresolutionmedi-
ator, will play an important role in human pregnancy. In fact,
level of lipoxin A4 in nonpregnant women is significantly
lower than that in pregnant women, and circulating level of
lipoxinA4 in pregnantwomendisplayed amodest but signifi-
cant increase throughout pregnancy [48].Thus, it is tempting
to speculate that inadequate production of lipoxin A4 can
lead to abnormality of placental immunomicroenviroment,
increasing the risk of preeclampsia. This has been confirmed
by our results from clinical study that level of lipoxin A4
in preeclampsia is significantly lower than that in nor-
mal pregnancy. Additionally, our results from animal study
demonstrated that lipoxin A4 could suppress the increased
production of proinflammatory cytokines and alleviate the
symptoms of preeclampsia in LPS-induced rat model for
human preeclampsia [49]. Moreover, results from our previ-
ous study verified that lipoxin A4 can inhibit the enhanced
IL-1𝛽 production of monocytes from severe preeclampsia
women [50]. Recently, preliminary results from animal study
indicated that lipoxin A4 may participate in the regulation
of rat fetomaternal immune tolerance in early pregnancy.
Therefore, lipoxin A4, an endogenous anti-inflammatory
and proresolution mediator, is a key player in terminating
exaggerated inflammatory responses and restoring maternal
systemic homoeostasis in pregnancy.
There exists an interrelationship between lipoxin A4 and
V-ATPase. In fact, this is the case. The recent findings by
Russell et al. found that lipoxinA4 is a novel estrogen receptor
modulator and exhibits estrogenic activity in vivo, revealing
a previously unappreciated facet of various bioactions of
this anti-inflammatory and pro-resolution mediator [51].
Thus, lipoxin A4 may exert an important role in regulating
Abnormal V-ATPase
Abnormal fetomaternal
immune interaction
and lipoxin A4)
Placental damage
Preeclampsia
endocrine system
Abnormal maternal
(i.e., abnormal RAS) (i.e., abnormal 1,25(OH)2D3
Figure 3: A proposed model that placental V-ATPase function is a
key link between multiple causes of preeclampsia.
the V-ATPase expression, as V-ATPase expression level is
estrogen dependent, which has beenmentioned earlier in this
review. In addition, V-ATPase may also participate in the
modulation of lipoxinA4 bioactions.There is evidence impli-
cating that V-ATPase may get involved in the complex
interaction between lipoxin A4 and its receptor in lipoxin
A4-stimulated signal pathways. Maderna et al. reported
that internalization and trafficking is critical for LXA4-
stimulated phagocytosis in the resolution of inflammation
[52]. Transmembrane receptors internalization is of physio-
logical importance, which is required for right signal trans-
duction, proper dissociation of ligand from receptor, and
receptor-mediated endocytosis. Although receptor internal-
ization may occur in different ways, V-ATPase-mediated
intraendosomal pathway is the main endocytic trafficking
machinery [53]. Therefore, internalization and trafficking of
lipoxin A4 receptor is likely to require the right assembly
and activity of V-ATPase in the endocytic complex of ALXR
internalization. If there is some defect inV-ATPase, biological
actions of LXA4 through ALXR could be severely hindered.
In summary, lipoxin A4 may play an important role in
modulating V-ATPase activity during pregnancy while the
key role of lipoxinA4 in fetomaternal immunoregulation also
depends on normal V-ATPase activity extensively.
6. Proposed Model and Conclusion
Based on the previous novel findings, a model of how pla-
cental V-ATPase function can be a key link between multiple
causes of preeclampsia is proposed (Figure 3). On one hand,
V-ATPase is an essential modulator in regulating bioaction of
RAS, 1,25(OH)2D3, and lipoxin A4 during pregnancy. On the
other hand, key roles of RAS, 1,25(OH)2D3, and lipoxin A4
can be integrated into the V-ATPase function in pregnancy.
Right cross-talk between V-ATPase and RAS, 1,25(OH)2D3,
and lipoxin A4 can facilitate normal placentation and ensure
successful pregnancy. Once disorder of V-ATPase activity
takes place at the fetomaternal interface, various bioactivity
of RAS, 1,25(OH)2D3, and lipoxin A4 will come into great
trouble, and vice versa. Any abnormality occurring at the
interaction between V-ATPase and RAS, 1,25(OH)2D3 and
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lipoxin A4 could cause a defective placenta, which will be
eventually involved in the progression of preeclampsia. Over-
all, the previous proposal not only suggests the importance of
V-ATPase in modulating essential components of maternal
endocrine system (RAS) and key molecules of fetomaternal
immune interaction (1,25(OH)2D3 and lipoxin A4), but also
shows the key role of RAS, 1,25(OH)2D3, and lipoxin A4 in
regulating V-ATPase function.
Almost all cases of preeclampsia are associated with
poor placentation. Maternal endocrine system and immune
responses have been long considered to be involved in normal
placenta development. The renin-angiotensin system is a
typical endocrine hormone system that plays a key role
in regulating placentation as well as maintaining normal
pregnancy. Recently, the immunomodulation of vitamin D
in pregnancy has been proposed as a key aspect of pla-
cental homoeostasis. Additionally, lipoxin A4, as an anti-
inflammatory and proresolution mediator, has been demon-
strated to be vital in modulating fetomaternal immune
tolerance during pregnancy. Nevertheless, the complexity of
variousmolecular events that occur at the fetomaternal inter-
face in placenta development is far from being completely
elucidated. A series of molecular mechanisms needs to be
coordinated for establishing a perfect placenta, while any
deviation from this ordered course of molecular events may
result in pregnancy complications, such as preeclampsia. V-
ATPase, a key molecule in placentation, is beginning to be
appreciated. It is closely linked to renin-angiotensin system,
1,25(OH)2D3, and lipoxin A4. Therefore, it may work as a
key link between multiple causes of preeclampsia. Further
studies regarding V-ATPase-related molecular mechanisms
necessary for placentation are required, since clinical inter-
vention to these potential dysregulatedmolecular events may
eventually improve pregnancy outcome.
6.1. Further Research Directions
(1) Determe the detailed role of V-ATPase in fetoplacen-
tal unit.
(2) Clarify the potential role of placental V-ATPase in
preeclampsia.
(3) Investigate the nature of interaction between V-
ATPase and RAS, 1,25(OH)2D3, and lipoxin A4 in
normal pregnancy.
(4) Investigate the causes of abnormal interaction
between V-ATPase and RAS, 1,25(OH)2D3, and
lipoxin A4 in preeclampsia.
(5) Understand the mechanisms of placental damage
associated with defective V-ATPase, RAS,
1,25(OH)2D3 and lipoxin A4 in preeclampsia.
(6) Study the effect of potential therapeutic agents on
placental damage and maternal clinical signs of
preeclampsia.
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